0
Clinical Investigations: LUNG CANCER |

Decision-Tree Sensitivity Analysis for Cost-Effectiveness of Chest 2-Fluoro-2-D-[18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Pulmonary Nodules (Non-small Cell Lung Carcinoma) in Japan*

Shigeru Kosuda, MD; Kiyoshi Ichihara, MD, PhD; Masumi Watanabe, MD; Hideo Kobayashi, MD, FCCP; Shoichi Kusano, MD
Author and Funding Information

*From the Department of Radiology (Dr. Kosuda), Department of Surgery (Dr. Watanabe), and Department of Internal Medicine (Dr. Kobayashi), National Defense Medical College, Tokorozawa, Japan; and the Department of Diagnosis (Dr. Ichihara), Kawasaki Medical College, Kurashiki, Japan. Partially supported by funding from the Working Group Project of the Japanese Society of Nuclear Medicine.

Correspondence to: Shigeru Kosuda, MD, Department of Radiology, National Defense Medical College, 3–2 Namiki Tokorozawa 359-8513, Japan; e-mail: nucleark@infokanto.ne.jp



Chest. 2000;117(2):346-353. doi:10.1378/chest.117.2.346
Text Size: A A A
Published online

Context: Recent studies have demonstrated the potential cost-effectiveness of using 2-fluoro-2-D-[18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in the management of non-small cell lung carcinoma (NSCLC), but because of differences in health-care systems, those findings may not hold true in a Japanese hospital.

Objective: To assess the cost-effectiveness of the chest CT plus chest FDG-PET strategy in Japan.

Design: Decision-tree sensitivity analysis based on the two competing strategies of chest CT–alone vs chest CT plus chest FDG-PET.

Study selection: A simulation of 1,000 patients in whom NSCLC, stage IIIB or less, was suspected was created using baselines of other relevant variables in regard to sensitivity, specificity, mortality, life expectancy, and cost from published data.

Methods: We surveyed the relevant literature for the choice of variables.

Main outcome measures: Expected marginal cost and expected life expectancy gain for NSCLC patients.

Results: The chest CT plus chest FDG-PET strategy yielded an expected life expectancy gain of 0.607 years (7.3 months) per patient, compared with the alternative strategy of chest CT–alone. Using an FDG-PET examination cost of 1.0 × 105 yen (around $700 US) per study, the cost increment was 2.18 × 105 yen/yr/patient.

Conclusions: The chest CT plus chest FDG-PET strategy in patients with NSCLC is unlikely to be cost-effective in Japan. However, patient life expectancy gain would increase as a result of improved staging of NSCLC. These preliminary results should be confirmed by further studies for specific environments.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543